首页> 外文期刊>Neuroscience: An International Journal under the Editorial Direction of IBRO >Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain.
【24h】

Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain.

机译:鞘内白介素-1受体拮抗剂与可溶性肿瘤坏死因子受体结合在神经性疼痛的大鼠模型中表现出抗异常性疼痛作用。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The expression of interleukin-1beta and tumor necrosis factor has previously been shown to be up-regulated in the spinal cord of several rat mononeuropathy models. This present study was undertaken to determine whether blocking the action of central interleukin-1beta and tumor necrosis factor attenuates mechanical allodynia in a gender-specific manner in a rodent L5 spinal nerve transection model of neuropathic pain, and whether this inhibition occurs via down-regulation of the central cytokine cascade or blockade of glial activation. Interleukin-1 receptor antagonist or soluble tumor necrosis factor receptor was administered intrathecally via lumbar puncture to male Holtzman rats in a preventative pain strategy, in which therapy was initiated 1h prior to surgery. Administration of soluble tumor necrosis factor receptor attenuated mechanical allodynia, while interleukin-1 receptor antagonist alone was unable to decrease allodynia. Interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor, administered to both male and female rats in a preventative pain strategy, significantly reduced mechanical allodynia in a dose-dependent manner (P<0.01). The magnitude of attenuation in allodynia was similar in both males and females. Immunohistochemistry on L5 spinal cord revealed similar astrocytic and microglial activation regardless of treatment. At days 3 and 7 post-transection, animals receiving daily interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibited significantly less interleukin-6, but not interleukin-1beta, in the L5 spinal cord compared to vehicle-treated animals. In an existing pain paradigm, in which treatment was initiated on day 7 post-transection, interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor attenuated mechanical allodynia (P<0.05) in male rats. These findings further support a role for central interleukin-1beta and tumor necrosis factor in the development and maintenance of neuropathic pain through induction of a proinflammatory cytokine cascade.
机译:先前已证明白介素-1β和肿瘤坏死因子的表达在几种大鼠单神经病模型的脊髓中被上调。进行本研究是为了确定在神经病性疼痛的啮齿动物L5脊髓横断模型中,阻断中央白细胞介素1β和肿瘤坏死因子的作用是否以性别特异性方式减弱机械性异常性疼痛,以及这种抑制作用是否通过下调而发生中枢细胞因子级联或神经胶质激活的阻断。通过预防性疼痛策略,通过腰椎穿刺术对雄性Holtzman大鼠鞘内注射白介素1受体拮抗剂或可溶性肿瘤坏死因子受体,该方法在手术前1小时开始。可溶性肿瘤坏死因子受体的管理可减轻机械性异常性疼痛,而白介素-1受体拮抗剂无法降低异常性疼痛。以预防性疼痛策略对雄性和雌性大鼠给药的白介素-1受体拮抗剂与可溶性肿瘤坏死因子受体联合,以剂量依赖的方式显着降低了机械性异常性疼痛(P <0.01)。男性和女性中异常性疼痛的衰减幅度相似。无论治疗如何,L5脊髓的免疫组织化学显示相似的星形胶质细胞和小胶质细胞活化。在横断后第3天和第7天,与媒介物治疗的动物相比,每天接受白介素1受体拮抗剂与可溶性肿瘤坏死因子受体联合治疗的动物在L5脊髓中的白介素6显着较少,但白介素1β没有。在现有的疼痛范例中,在横断后第7天开始治疗,白介素1受体拮抗剂与可溶性肿瘤坏死因子受体联合可减轻雄性大鼠的机械性异常性疼痛(P <0.05)。这些发现进一步支持中枢白细胞介素-1β和肿瘤坏死因子通过诱导促炎性细胞因子级联反应在神经性疼痛的发生和维持中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号